A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b.
Glycoconjugate vaccines provide effective prophylaxis against bacterial infections. To date, however, no commercial vaccine has been available in which the key carbohydrate antigens are produced synthetically. We describe the large-scale synthesis, pharmaceutical development, and clinical evaluation of a conjugate vaccine composed of a synthetic capsular polysaccharide antigen of Haemophilus influenzae type b (Hib). The vaccine was evaluated in clinical trials in Cuba and showed long-term protective antibody titers that compared favorably to licensed products prepared with the Hib polysaccharide extracted from bacteria. This demonstrates that access to synthetic complex carbohydrate-based vaccines is feasible and provides a basis for further development of similar approaches for other human pathogens.
Center for the Study of Synthetic Antigens, Facultad de Química, Universidad de la Habana, Ciudad Habana, Cuba, 10400. vicente@fq.uh.cu
V
V
Verez-Bencomo
V
V
Fernández-Santana
Eugenio
E
Hardy
Maria E
ME
Toledo
Maria C
MC
Rodríguez
Lazaro
L
Heynngnezz
Arlene
A
Rodriguez
Alberto
A
Baly
Luis
L
Herrera
Mabel
M
Izquierdo
Annette
A
Villar
Yury
Y
Valdés
Karelia
K
Cosme
Mercedes L
ML
Deler
Manuel
M
Montane
Ernesto
E
Garcia
Alexis
A
Ramos
Aristides
A
Aguilar
Ernesto
E
Medina
Gilda
G
Toraño
Iván
I
Sosa
Ibis
I
Hernandez
Raydel
R
Martínez
Alexis
A
Muzachio
Ania
A
Carmenates
Lourdes
L
Costa
Félix
F
Cardoso
Concepción
C
Campa
Manuel
M
Diaz
René
R
Roy
D000328:Adult; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D002675:Child, Preschool; D004311:Double-Blind Method; D006001:Glycoconjugates / Q000276:immunology; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D011134:Polysaccharides / Q000138:chemical synthesis* / Q000276:immunology* / Q000302:isolation & purification; D011135:Polysaccharides, Bacterial / Q000276:immunology* / Q000302:isolation & purification; D013745:Tetanus Toxoid / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology
D000907:Antibodies, Bacterial; D006001:Glycoconjugates; D018073:Haemophilus Vaccines; D007074:Immunoglobulin G; D011134:Polysaccharides; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate; C008984:polyribitol phosphate